Intensive Dietary and Activity Counselling (IDAC)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

800 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-15

Study Completion Date

2031-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this intervention study is to investigate if a intensive dietary and physical activity counselling during the first two years of life in children with increased (genetically) risk for Type 1 Diabetes (T1D) can promote a healthy beta-cell environment, in order to reduce increased weight gain and development of islet autoimmunity (beta-cell autoantibodies).

The main hypotheses are:

* Early lifestyle influences the susceptibility to islet autoimmunity (IA) by increasing beta-cell vulnerability. Introducing a "healthy beta-cell lifestyle" from infancy will reduce beta-cell vulnerability and the likelihood of IA.
* Will promotion of a healthy beta-cell environment during early childhood in children with increased genetic risk of T1D reduce beta-cell stress, increased weight gain and development of islet autoantibodies?

Primary outcome will be measured by development of IA and by the proinsulin/C-peptide ratio during an OGTT. Secondary outcomes are accelerated growth during infancy, overweight at the age of 36 months.

Participants will be randomized (ratio 1:1) to control group and intervention group. Breastfeeding status at time of randomization will be taken into account.

Participants will be enrolled by the age of four months and visit the research clinic ever third months up until the age of 24 months, and then yearly up until the age of 6 years.

* Anthropometric measurements and blood draw will be taken at each visit.
* Questionnaires focusing on breastfeeding and early infant feeding habits will be used at each visit.
* 24hrs recalls will be done at the age of 6, 9, 12, 18 and 24 months of age.
* Physical activity will be estimated using questionnaires (3, 6, 9 months) and accelerometer data (18 and 24 months).
* Stool samples will be collected at 6, 12 and 18 months of age

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T1D Closed-loop and Physical Activity

NCT06460558

Diabetes type1

RECRUITING

The Integration of Physical Activity Into the Clinical Decision Process of People with Type 1 Diabetes

NCT05670366

Type 1 Diabetes

COMPLETED NA

Childhood Diabetes

NCT00804232

Diabetes, Type I

UNKNOWN NA

Sports Participation in Children and Adolescents With Type 1 Diabetes Mellitus

NCT03291834

Diabetes Mellitus

COMPLETED

Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention

NCT02510664

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim is to test previously described associations between increased growth, diet and physical activity and the development of type 1 diabetes-related autoantibodies. In a randomized trial, it is investigated whether intensive counseling regarding diet and physical activity already during infancy affects metabolism (beta-cell health), growth and the risk of type 1 diabetes-related autoantibodies.

Rapid growth and/or weight gain during childhood has been shown in previous studies to be associated with an increased risk of developing type 1 diabetes-related autoantibodies (IA, IA-2A, GADA, ZnT8RA, ZnT8WA), a precursor to autoimmune type 1 diabetes. Rapid growth can, in theory, stress the beta cells through an increased need for insulin and make them more susceptible to an autoimmune attack. Adipocytokines and inflammatory cytokines secreted from adipose tissue and overload induced by circulating nutrients have been discussed to play a role in the pathogenesis of autoimmune diseases through their impact on immune cell function and activation.

Although previous research has used different measures of weight gain and obesity (BMI, body fat%, growth rate), the results are relatively consistent and show a link between overweight and obesity in early years and an increased risk of beta cell autoimmunity and progression to type 1 diabetes. Specific growth patterns during early childhood have also been associated with type 1 diabetes-related autoantibodies and progression to T1D in children at genetic risk.

Dietary protein intake has been considered a key player in regulating body weight in infants based on results from both intervention and observational studies. A high protein intake, especially from animal sources, has been suggested to affect the development and function of the immune system, potentially contributing to the development of autoimmune diseases such as type 1 diabetes. In addition, previous studies have shown a link between cow's milk consumption (both age at first introduction and quantity) with the risk of T1D. However, exactly how this happens is not entirely clear, and more research is needed to better understand the connections. Previous studies have shown that children who had a high protein intake during the first year of life had a slightly higher risk of developing T1D-related autoantibodies. There is some evidence to suggest that both the energy and protein content of the diet may influence the risk of developing T1D, particularly through mechanisms related to growth, weight gain, and immune response. However, the evidence is not entirely consistent and more research is needed to clarify these relationships and mechanisms. According to the 'early protein hypothesis', a high intake of protein during early childhood stimulates growth, especially adipose tissue, and later leads to an increased risk of obesity. The hypothesis is that a high-protein diet in early childhood may increase levels of insulin-releasing amino acids (branched-chain amino acids), which in turn may stimulate insulin- and insulin-like growth factor 1 (IGF-1) secretion.

In this study, the investigators will test previously described associations by including infants with an increased genetic risk of T1D in a randomized trial, where the parents receive either the usual advice given by the child health center or an intensive counseling regarding diet and physical activity. All children are monitored for growth, metabolic parameters and development of type 1 diabetes-related autoantibodies.

During the intervention period (3 months - 2 years of age), the study will focus on the following:

1. Support continued breastfeeding up to 12 months of age.
2. Advise families on diet and physical activity during infancy in accordance with national/international recommendations.
3. Study growth patterns in infants/children through anthropometric measurements (weight, height) and body composition (skin fold measurement).

The primary endpoint is beta-cell health at 36 months of age, assessed as the proinsulin/C-peptide ratio at glucose load (OGTT).

Secondary endpoints are:

* accelerated growth during infancy
* overweight at 36 months of age
* time to development of persistent confirmed islet autoantibodies or type 1 diabetes

Visits to the research clinic take place every three months up to the age of 3, then once a year up to the age of 6.

Study duration per research participant; minimum 4 months of age to 3 years of age, maximum of 3 months of age to 6 years of age.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes Autoimmune Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group (IDAC+)

Participants randomized to the IDAC+ will regularly receive dietary and physical activity advice with focus on continuing breastfeeding up until the age of 12 months, limit the protein intake in the child´s diet (maximum 15E%), limit milk \& milk products (max 150 ml/day), support daily vitamin D supplementation. Specific age-appropriate advice on physical activity will be given to participants.

Group Type EXPERIMENTAL

IDAC+

Intervention Type BEHAVIORAL

Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.

Control Group

No specific advice will be given to this group other than national guidelines similar to those given by the childcare centers.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IDAC+

Diet and physical activity counselling at baseline, 6, 12 and 24 months visit.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The age of the infant at time of enrolment should be 3.0 months (13 - 17 weeks).
* An increased genetic risk (7-10%) to develop beta-cell autoantibodies by the age of 6 years.

* for males having a genetic risk score greater than or equal to 18.2 but excluding those who are eligible for AVANT1A.
* for females having a genetic risk score greater than or equal to 14.5 but excluding those who are eligible for AVANT1A.

Children with a T1D-FDR, all DR3/3, DR4-DQ8/DR4-DQ7 and DR4-DQ8/x where x is none of the following protective alleles: DRB1\*1501, DQB1\*0503, DRB1\*1303 will be included regardless of genetic risk score.

\- Written informed consent signed by the custodial parent(s).

Exclusion Criteria

* Any medical condition, concomitant disease or treatment that may interfere with the assessments or may jeopardize the participant's safe participation in the study, as judged by the investigators.
* Preterm delivery \< 36 weeks of gestation.
* Any condition that could be associated with poor compliance.
* Diagnosis of diabetes prior to recruitment or randomization.
* Current use of any investigational drug.

Minimum Eligible Age

3 Months

Maximum Eligible Age

4 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No